San FranciscoCalifornia’s high court ruled 6-1 for Gilead.
Drugmakers can delay a safer successor until the current patent nears expiry, turning the delay into fresh exclusivity.
Court filings show more than 24,000 plaintiffs alleging kidney and bone damage now have no legal claim.
Sources: STAT